{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Medpace Holdings, Inc.
Medpace Holdings Reaches New 52-Week High of $514.74
Medpace Holdings, Inc. achieved a new 52-week high of USD 514.74 on September 30, 2025, reflecting strong market performance with a 1-year increase of 26.74%. The company, with a market cap of USD 13,859 million, showcases impressive financial metrics, including a return on equity of 242.70%.
Is Medpace Holdings, Inc. technically bullish or bearish?
As of July 31, 2025, Medpace Holdings, Inc. shows a bullish technical trend with strong momentum indicators, despite some mixed signals in the KST and OBV, and has significantly outperformed the S&P 500 year-to-date and over three years.
Is Medpace Holdings, Inc. overvalued or undervalued?
As of September 3, 2025, Medpace Holdings, Inc. is considered very expensive with a high P/E ratio of 21 compared to peers, despite strong returns, indicating it may be overvalued at its current price of 501.94.
Medpace Holdings Hits New 52-Week High of $506.55, Showcasing Strong Growth
Medpace Holdings, Inc. achieved a new 52-week high of USD 506.55 on September 17, 2025, reflecting strong market performance with a 22.71% increase over the past year. The company, with a market cap of USD 13,859 million, showcases impressive financial metrics, including a return on equity of 242.70%.
Is Medpace Holdings, Inc. overvalued or undervalued?
As of March 5, 2025, Medpace Holdings, Inc. is considered fairly valued with a P/E ratio of 21, an EV to EBITDA of 16.73, and a PEG ratio of 0.59, showing strong operational efficiency compared to peers, despite mixed recent stock performance.
Is Medpace Holdings, Inc. technically bullish or bearish?
As of June 6, 2025, Medpace Holdings, Inc. exhibits a mildly bearish trend, with mixed signals from various indicators, including a mildly bullish weekly MACD and a mildly bearish monthly MACD, alongside bearish daily moving averages and Bollinger Bands.
Who are in the management team of Medpace Holdings, Inc.?
As of March 2022, the management team of Medpace Holdings, Inc. includes Dr. August Troendle (Chairman, President, CEO), Mr. Fred Davenport (Lead Independent Director), and independent directors Mr. Brian Carley, Ms. Ashley Keating, Dr. Thomas King, and Mr. Robert Kraft.
What does Medpace Holdings, Inc. do?
Medpace Holdings, Inc. is a clinical contract research organization that offers drug and medical device development services. As of March 2025, it reported net sales of $559 million and a net profit of $115 million, with a market cap of approximately $8.58 billion.
How big is Medpace Holdings, Inc.?
As of Jun 18, Medpace Holdings, Inc. has a market capitalization of $8.58 billion, with net sales of $2.16 billion and net profit of $416.39 million over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
